Modality
Degrader
MOA
WEE1i
Target
IL-17A
Pathway
Epigenetic
GBM
Development Pipeline
Preclinical
~Sep 2012
→ ~Dec 2013
Phase 1
~Mar 2014
→ ~Jun 2015
Phase 2
~Sep 2015
→ ~Dec 2016
Phase 3
~Mar 2017
→ ~Jun 2018
NDA/BLA
Sep 2018
→ Jan 2027
NDA/BLACurrent
NCT04587796
2,196 pts·GBM
2018-09→2027-01·Recruiting
2,196 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-01-2010mo awayPh3 Readout· GBM
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2027-01-20 · 10mo away
GBM
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04587796 | NDA/BLA | GBM | Recruiting | 2196 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| MDG-611 | Madrigal Pharma | Approved | CGRP |